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Dipeptidyl peptidase-4 inhibitors 
improve arterial stiffness, blood pressure, lipid 
profile and inflammation parameters in patients 
with type 2 diabetes mellitus
Lea Duvnjak1,2 and Kristina Blaslov1*
Abstract 
Background: This uncontrolled open label study evaluated the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i): 
sitagliptin and vildagliptin on augmentation index standardized for 75 beats per minute (cAiX@75), blood pressure 
(BP), lipid profile and high-sensitivity C-reactive protein (hsCRP) in patients with type 2 diabetes mellitus (T2DM).
Methods: Fifty-one well-regulated T2DM patients were randomly assigned to either sitagliptin or vildagliptin 
(100 mg/day) for 3 months continuing their previous treatment. Lipid profile, cAiX@75, hsCRP, glycated hemoglobin 
(HbA1c) were measured at baseline at 4, 8 and 12th week were accessed. cAiX@75 and pulse wave velocity (PWV) 
were determined by SphygmoCor device.
Results: Following DPP-4 treatment there was a significant reduction in total serum cholesterol (5.18 vs 
4.62 mmol/L), low-density lipoprotein (2.89 vs 2.54 mmol/L), hsCRP (3.21 vs 1.95 mg/L), cAiX@75 (24.5 vs 22.3) and 
central systolic BP (131.8 vs 119.5 mmHg). The sitagliptin treated group reached cAiX@75 reduction earlier in the 
study period while neither sitagliptin or vildagliptin use resulted in the significant HbA1c reduction.
Conclusion: The treatment with DPP-4i: sitagliptin and vildagliptin provides favorable metabolic and vascular effects 
beyond glucose-control. Further studies are required to elucidate their implication in metabolic pathways.
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Background
According to the Framingham study type 2 diabetes mel-
litus (T2DM) is associated with a twofold to fourfold 
increased risk for cardiovascular disease (CVD) [1]. This 
is due to diabetes related metabolic disorders: chronic 
hyperglycemia and dyslipidemia along with oxidative 
stress and low grade inflammation [2]. Although antihy-
perglycemic drugs improve glycemic control, the cardio-
vascular benefits to certain subgroups of T2DM patients 
has been established only for metformin and pioglitazone 
[3, 4]. There is a lack of evidence that the therapeutic 
strategies targeting pancreatic β cell dysfunction and 
insulin resistance (IR) reduce the cardiovascular risk in 
patients with diabetes [5]. This notion raises the need 
for alternative therapies that provide substantial benefits 
without side effects. Among emerging anti-diabetic can-
didates, incretin-based therapies carry a special cardio-
vascular implication.
Incretins are a group of gastrointestinal hormones, 
among which the glucagon-like peptide 1 (GLP-1) and 
the glucose dependent insulinotropic peptide (GIP) are 
released in response to nutrient ingestion, stimulating 
insulin and suppressing glucagon secretion [6]. GLP-1 
also seems to have some beneficial effect on pancreatic 
β-cells preservation in experimental models [7]. How-
ever, this actions are limited due to its rapid inactiva-
tion by the dipeptidyl peptidase-4 (DPP-4) enzyme [8, 
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9]. DPP-4 inhibitors spare the GLP-1 breakdown and 
improve glycemic control by consequential increase insu-
lin secretion [9, 10].
Beyond its beneficial action on metabolic control, 
GLP-1 seems to exert favorable cardiovascular effect 
mediated partially through a specific GLP-1 receptor 
on cardiomyocytes, vascular endothelium and vascular 
smooth muscle cells [10]. The administration of inher-
ent GLP-1 causes acute animal aortic dilation [11]. This 
observed vasodilatory properties are probably mediated 
through GLP-1 metabolites and independently of the 
GLP-1 receptor, acting instead through an NO/cGMP-
dependent mechanism [12].
DPP-4 has several non-incretin substrates involved in 
inflammation, immunity and cardiovascular system [13] 
and its expression on endothelial surface suggests that 
its inhibition might reduce the vascular tone [14]. Some 
clinical data suggest the beneficial effects of DPP-4 inhib-
itors on hypertension, dyslipidemia and CRP have been 
cited in the literature [15–18]. This suggests that those 
might have a potential to reduce the CVD burden among 
patients with T2DM.
Arterial stiffness (AS) is a strong independent predictor 
of CVD in several populations, including T2DM patients 
[19] being increasingly recognized as a surrogate end 
point for CVD [20]. The effect of DPP-4 inhibition on 
AS is still a matter of debate [15–17] and the direct com-
parison of different DPP-4 inhibitors impact on CVD risk 
factors is yet to be established.
Thus, we aimed to evaluate the effect of DPP-4 inhibi-
tors on CVD risk factors: central obesity, lipidemia, 
hsCRP, glycaemia and blood pressure with a special 
emphasis on AS and related parameters, i.e. central pulse 
pressure (PP), central blood pressure (cBP) and pulse 
wave velocity (PWV) in metabolically well regulated 
T2DM patients. Second we compared the effect of two 
different DPP-4 inhibitors: sitagliptin and vildagliptin on 
the observed parameters.
Methods
This was an uncontrolled open-label, parallel-arm, rand-
omized 12 week study conducted in the In-patient Clinic 
for Diabetes, endocrinology and metabolic diseases Vuk 
Vrhovac, Zagreb, Croatia.
Type 2 diabetic patients of either gender, aged between 
40 and 75  years were eligible for the inclusion in the 
study. Selected non-inclusion criteria were insulin or 
(current or previous 3 months) treatment with any incre-
tin-based treatment strategy including GLP-1 analogues 
and DPP-4 inhibitors. Furthermore, patients with mac-
rovascular complications such as significant arterial 
obliteration detected by imaging methods, an acute car-
diovascular event (e.g. myocardial infarction), unstable 
angina or stroke within six months prior to enrollment, 
impaired glomerular filtration rate (<60 ml/min/1.73 m2) 
and urine albumin excretion rate >300 mg/24 h.
After the screening period patients were randomized 
to receive either sitagliptin (50 mg twice daily) or vilda-
gliptin (50 mg twice daily) in addition to continuing their 
antidiabetic background treatment. Also, the antihyper-
tensive and lipid-lowering drugs were unchanged during 
the study period. Randomization procedures were per-
formed by principal investigator or his/her delegate by 
physical method of randomization using shuffle sealed 
envelopes with treatment allocations inside. Patients 
both groups were instructed to strictly maintain dietary 
habits and daily activities during the course of the study. 
They were assessed at the outpatient visit four times: at 
baseline, 4, 8 and 12th week. Blood samples for biochem-
ical measurements were collected at each visit as well as 
physical examination including anthropometric param-
eters while the carotid-femoral (cf ) PWV and 24-h blood 
pressure record was measured at baseline and at the end.
The study protocol was approved by the Ethic Commit-
tee of the Merkur University Hospital, Zagreb, Croatia 
and the study was performed according to Declaration 
of Helsinki and “good clinical practice” (GCP) guidelines. 
Written informed consent was obtained from all the 
study participants before the study entry.
The central aortic pressure waveform can be used to 
determine central systolic and diastolic BP, (dBP) cen-
tral PP and augmentation pressure (AP). Central PP and 
augmentation index (cAIx; AP as a proportion of PP) are 
markers of AS showing good correlation with cardiovas-
cular morbidity an mortality [21, 22]. The central arte-
rial waveform was derived by using the SphygmoCor™ 
System (AtCor Medical, Sydney, Australia). The radial 
artery waveform was recore from the radial artery at the 
wrist, using high-fidelity applanation tonometry (Millar 
Instruments, Houston, Texas). The SphygmoCor™ Sys-
tem automatically generates the corresponding central 
(aortic) waveforms from an averaged radial artery wave-
form. From the central systolic and diastolic BP as well as 
AP and cAIx were derived. The cAIx was normalized to 
hearth rate of 75 beats per minute (cAIx@75).
PWV is a direct measure of AS of large arteries. For 
the determination of aortic PWV, waveforms of the com-
mon carotid artery and femoral artery were obtained 
using SphygmoCor™. PWV was calculated as the dis-
tance between suprasternal notch and the femoral artery 
recording site, and divided by the time interval between 
the feet of the flow waves.
Three readings were obtained from the right arm of 
seated participants while their arm was supported at 
heart level; 1 trained observer took all measures using 
an automatic office BP device (OMRON Intellisense 
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HEM-907) according to JNC VIII criteria [23]. For 24-h 
ambulatory blood pressure (ABP) measurements, partici-
pants were fitted with a SpaceLabs 90207 ABP monitors. 
The cuff was secured around the participant’s non-dom-
inant arm, and it remained there during the entire test. 
Measurements were automatically repeated if an error 
occurred. The adult cuff and the large adult cuff were 
used for arm circumferences of 24–31 and 32–42  cm, 
respectively.
Body weight (BW) was measured with light clothing on 
a balance scale and height to the nearest 0.5 cm using a 
meter that was stabilized on the wall. BMI was calculated 
as weight (kilograms) divided by height (meters) squared. 
Waist circumference was measured at minimal respira-
tion by a flexible tape parallel to the floor and immedi-
ately above the iliac crest.
All laboratory tests were performed after a 12 h over-
night fast. Biochemistry, including glucose, lipid levels 
(TC; high density lipoprotein cholesterol, HDL-C; and 
TG) liver enzymes (alanine transaminase, ALT; aspartate 
transaminase, AST, hsCRP and creatinine, were evalu-
ated on an Olympus analyzer (Olympus AU600, Olym-
pus Optical Co., Tokyo, Japan). Low-density lipoprotein 
cholesterol (LDL-C) was calculated using Friedewald’s 
formula [24].
To perform a formal sample size calculation the pri-
mary endpoint was set to be the effect of sitagliptin and 
vildagliptin on central SBP [15]. We estimated that a total 
of 51 patients will be needed for this two-treatment par-
allel-design study with the probability (power) of 99 per-
cent that the study will detect a treatment difference at a 
two-sided 0.05 significance level. All the data are entered 
in triplicate in Open Document Spreadsheet database 
and the analysis was performed using SPSS 17.0 (Chi-
cago, IL, USA).
Normality of distribution was confirmed by Shap-
iro–Wilk test prior to further analysis. Normally distrib-
uted data were compared by paired t test and two-way 
ANOVA and expressed as mean ± standard deviation. A 
two sided P value <0.05 was considered significant.
Results
Fifty-one patient were enrolled in the study and all of 
them completed all four visits. There were 30 (58.8  %) 
males. Vildagliptin 2 × 50 mg/day was added to current 
diabetes therapy reigment in 20 (39.21 %) patients at the 
point treated with metformin only (up to 3  g; N =  17) 
and 3 patients with gliclazide 60  mg/day  +  metformin 
2  g/day. Sitagliptin 2  ×  50  mg/day was added to 31 
(60.79 %) patient treated with metformin (up to 3 g/day; 
N =  30) and one patient treated with metformin (2.5  g 
and gliclazide 60 mg/day).
After 12-weeks of treatment with DPP-4 inhibitors, 
BMI remained almost unchanged [(28.8 (3.5) kg/m2 vs 
28.6 (3.5) kg/m2), p = NS] while the waist circumference 
significantly decreased mean HbA1c value remained 
unchanged (Table  1). The group experienced a mean 
−4.41 (2.03) mmHg of 24-hour SBP reduction and −4.65 
(2.36) mmHg 24-hourDBP reduction. Total and well as 
LDL cholesterol significantly dropped as well as hsCRP 
concentration. The treatment also resulted in triglycer-
ides concentration reduction (Table 1).
A significant reduction in cAIX@75, central SBP, DBP 
as well as office SBP and DBP was observed (Table  2). 
The PWV change of −0.40 (0.90) m/s was also notified, 
however, it did not reach the statistical significance [8.59 
(0.33) vs 8.42 (0.28), p = 0.816].
To evaluate the pharmacological action of DPP-4 
inhibitors more precisely, we analyzed the results of 
DPP-4 treated cohort by stratifying them to sitaglip-
tin and vildagliptin treated group. Sitagliptin resulted 
in significant oSBP [136.2 (12.3) vs 131.7 (10.5) mmHg, 
p  =  0.037] and oDBP [84.8 (6.8) vs 74.1 (9.8) mmHg, 
p  =  0.001] reduction while vildagliptin reached the 
significance only regarding oDBP [82.3 (10.1) vs 77.2 
(10.4) mmHg, p  =  0.007]. cDBP was also significantly 
reduced only for sitagliptin group (78.8 (9.6) vs 73.8 (9.6) 
mmHg, p  =  0.002). In addition, hsCRP reduction was 
significant only for the sitagliptin group and was supe-
rior to vildagliptin [−0.84 (0.31) vs −0.31 (0.03) mg/L, 
p  =  0.017]. Sitagliptin was superior to vildagliptin in 
cAiX@75 reduction in the 8th week of the study (25.3 
vs 26.4, p =  0.006), however, the difference was lost by 
the study end (Fig. 1a). Finally, at the 12th week sitaglip-
tin treated group had significantly lower cSBP compared 
to vildagliptin group (117.8 vs 122.4, p = 0.046) (Fig. 1b) 
Table 1 Clinical characteristics at  the begining and  at the 
study end (N = 51)
Data are expressed as mean (SD), HbA1c gycated haemoglobin, Chol cholesterol, 
HDL-C high density cholesterol, LDL-C low density cholesterol, Tgc triglycerides, 
hsCRP high sensitive C-reactive protein
Baseline 12-weeks after P
Waist circumference (cm) 103.3 (12.3) 101.4 (11.8) 0.012
24 h SBP (mmHg) 125.74 (13.41) 123.54 (10.87) <0.001
24 h DBP (mmHg) 74.49 (7.59) 73.67 (7.45) 0.281
HbA1c (%) 6.9 (1.1) 6.9 (0.7) 0.461
Cholesterol (mmol/L) 5.18 (1.0) 4.62 (1.60) 0.001
HDL-C (mmol/L) 1.29 (0.24) 1.31 (0.23) 0.973
LDL-C (mmol/L) 2.89 (0.84) 2.54 (0.85) 0.005
Triglycerides (mmol/L) 2.26 (1.35) 1.81 (0.91) 0.001
hsCRP (mg/L) 3.21 (0.86) 1.95 (1.59) 0.009
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although the reduction was not significant when com-
pared to the cSBP value at the study beginning for neither 
gliptin.
Discussion
The major finding of our study is that the 12-week treat-
ment with DPP-4 inhibitors reduces the AS, PWV and 
24-h SBP in T2DM patients. Furthermore, we showed 
that sitagliptin results in AS reduction earlier in the 
treatment period when compared to vildagliptin which 
might be due to their pharmacokinetic and pharmaco-
dynamics properties [25]. However, the use of DPP-4 i 
did not result in mean HbA1c change during the study 
period.
There is accumulating evidence on global increase in 
the rates of T2DM associated cardiovascular events 
[26]. Obesity related inflammatory mediators, such as 
hsCRP are increased in diabetic state so inflammation 
related oxidative stress along with dyslipidemia seems to 
play a key role in the pathogenesis of vascular dysfunc-
tion [27–30]. In addition, increased AS, reduced aortic 
dispensability was shown in diabetic compared to non-
diabetic population [31, 32]. Several studies reported AS 
as a strong predictor of cardiovascular morbidity and 
all-cause mortality in different populations and moreo-
ver, an independent predictor of 10-year mortality in 
patients with diabetes [21, 22].
Besides glycemic control, incretin-based treatment 
strategies for diabetes have focused on the reduction 
of CVD and its complications. There is a growing body 
of evidence suggesting that GLP-1-mimetics therapies 
have antiatherosclerotic and anti remodeling proper-
ties [11, 12]. However, if GLP-1 increase by DPP-4 inhi-
bition exhibits the same vascular profile remains to be 
established.
It was recently shown that 6 weeks treatment with saxa-
gliptin tends to improve central hemodynamics in T2DM 
patients [33]. Vildagliptin was reported to to improve AS 
in poorly regulated T2DM patients [34, 35] which is par-
tially in accordance with our results. In a study by Mis-
try et  al. [36] sitagliptin produced small but statistically 
significant reductions of 2–3  mmHg systolic and 1.6–
1.8 mmHg diastolic BP measurements acutely (day 1) and 
Table 2 Hemodynamic responses to  DPP-4 inhibitors 
in patients with type 2 diabetes during treatment
Data are expressed by mean (SD), AIX@75 augumentation index standardized for 
75 beats per minute, cSBP central systolic blood pressure, cDBP central diastolic 
blood pressure, oSBP office systolic blood pressure, oDBP office diastolic blood 
pressure
a  The large decrease in the cSBP and oSBP as well as STD which is large might 
be due to three patients who experienced a high cSBP reduction as follows: 
126–112, 133–116 and 146–124 mmHg while for the same patients the oSBP 
were: 132–111, 144–133 and 154–123 mmH
N = 51 Week 0 Week 4 Week 8 Week 12 P
AiX@75 24.5 (9.3) 23.4 (10.5) 23.2 (7.9) 22.3 (6.8) 0.031
cSBP (mmHg) 131.8 (12.9) 128.6 (11.7) 124.6 (10.5)a 119.5 (15.4)a 0.001
cDBP (mmHg) 79.8 (6.8) 79.0 (8.2) 77.5 (11.0) 77.2 (14.1) 0.003
oSBP (mmHg) 141.8 (10.2) 139.1 (13.1) 135.1 (12.1)a 131.8 (18.3)a 0.042
oDBP (mmHg) 82.7 (1.9) 78.8 (12.4) 78.2 (7.6) 75.6 (10.5) 0.001
Fig. 1 a Difference between sitagliptin and vildagliptin induced 
change in mean cAiX@75, b Difference between sitagliptin and 
vildagliptin induced change in mean cSBP
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at steady state (day 5) in nondiabetic patients with mild 
to moderate hypertension. Similar was reported recently 
by Marney et al. [37] in patients suffering from metabolic 
syndrome patients during placebo and low-dose ACE 
inhibition (5 mgenalapril), sitagliptin lowered blood pres-
sure. These results are highly supported by experimental 
animals studies: AS, as assessed by PWV, was signifi-
cantly increased in Western Diet fed mice (16 % increase) 
and was markedly decreased by DPP-4 inhibition [38].
We showed that both sitagliptin and vildagliptin 
treatment results in a significant hsCRP concentration 
reduction which is in accordance with the study data of 
Satoh-Asahara et al. [39] who were the first to report that 
sitagliptin treatment results in hsCRP reduction which 
was later confirmed for vildagliptin as well by Zografou 
et al. [35].
The addition of DPP-4 inhibitors to metformin (and 
gliclazide) also resulted in moderate waist circumference 
reduction. This is in agreement with previous studies 
and explained by the fact that although unlike mimetics, 
which boost GLP-1 activity leading to body weight reduc-
tion, DPP-4 inhibition works by slowing incretins deg-
radation, therefore the level of circulating GLP-1 in 
inhibition therapy is significantly increased [40]. Further-
more, Koren et al. [17] recently reported a significant tri-
glyceride concentration decrease in T2DM patients by 
0.2 ± 0.5 mmol/L following sitagliptin treatment, while the 
change in the total serum cholesterol, LDL- and HDL-cho-
lesterol did not reach the statistical significance. We also 
demonstrated a significant drop in triglyceride concentra-
tion, but in addition, we showed a significant LDL- and 
total serum cholesterol reduction which is in accordance 
with the data from the most recent meta-analysis discuss-
ing the DPP-4i on lipid profile [41]. Improvement of this 
common pattern of dyslipidemia in T2DM indicates that it 
might be a treatable risk factor for subsequent CVD.
Many pathophysiological mechanisms might explain 
these results. First, DPP-4 inhibition certainly acts 
partially throw increasing incretin levels (GLP-1) and 
the recent meta-analysis definitely indicate their car-
diac friendly lipid profile [42]. Previous animal studies 
have shown that GLP-1 can induce a NO-dependent 
or -independent relaxation of arteries [43, 44]. Second, 
the increased DPP-4 activity was reported in T2DM 
when accompanied with a significant degree of insulin 
resistance (IR) [43], i.e., DPP-4 was recently proposed 
as a novel adipokine linking obesity to metabolic syn-
drome (MS) [45–47]. It should be kept in mind that IR 
is often associated with abnormal lipid metabolism and 
hypertension, and those two traditional CV risk fac-
tors may explain the increase in AS in T2DM and MS as 
well as the potential benefit of DPP-4 inhibition derived 
therapies.
Conclusion
DPP-4 inhibitors could have a beneficial effect not only 
on blood glucose levels but also on blood pressure and 
artery function. It should be noted however that there are 
several limitations in our study. The greatest drawback 
of the study is the lack of placebo-treated group which 
emphasises the possibility that the DPP-4i observed 
therapy benefit might be due to lifestyle changes during 
the treatment period. In addition, due to small number 
of participants and 12-week follow up accompanied by 
the fact the study was uncontrolled and open-label, our 
results should be interpreted with caution. Further large 
randomized placebo controlled long-term studies are 
required to evaluate the effect of gliptines on vascular 
function, inflammation and dyslipidemia in patients with 
T2DM.
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